Articles

CardiAQ Valve Technologies, TMVI, second generation, implantation, Tor Vergata

CardiAQ Valve Technologies (CardiAQ) announced that its second-generation transcatheter bioprosthetic mitral heart valve was successfully implanted as a compassionate treatment. The device...

REDUCE FMR, Cardiac Dimensions, Carillon Mitral Contour System, FMR

Cardiac Dimensions announced the first patients have been enrolled in the REDUCE FMR clinical trial. REDUCE FMR is a prospective, double-blind, randomized multi-center trial, evaluating the...

Medtronic, CoreValve Evolut R, FDA approval, TAVR, recapturable

Medtronic plc announced the U.S. Food and Drug Administration (FDA) approval and U.S. launch of the recapturable, self-expanding CoreValve Evolut R System. The first-and-only recapturable and...

Edwards, Sapien 3, FDA approval, transcatheter heart valve

Edwards Lifesciences Corp. announced U.S. Food and Drug Administration (FDA) approval of the Edwards Sapien 3 valve with the Commander Delivery System for the treatment of high-risk patients...

Transmyocardial laser revascularization (TMLR or TMR) was introduced in the late 1990s as a method to offer relief to patients with incapacitating angina that were poor candidates for other...

Mitralign, transcatheter triscupid repair, TTVR, TR, first in human

A detailed reporting of the first successful case of a direct transcatheter tricuspid repair (TTVR) for severe TR has been reported by Prof. J. Schofer, M.D., of the Medicare Center and Department...

TAVR, Henry Ford Hospital, O'Neill, Greenbaum

Transcatheter aortic valve replacement (TAVR) is not only a breakthough minimally invasive medical therapy, but offers a new business opportunity for hospitals that begin a program. The technology...

October 10, 2014—Mitralign Inc. reported on the successful use of its technology to perform a percutaneous repair on a patient with tricuspid regurgitation (TR). Prof. Dr. med. J. Schofer of the...

Emboline Prosheath

While transcatheter aortic valve replacement (TAVR) is a paradigm shift in how valve disease is treated, one nagging safety issue that remains is TAVR’s stroke rate, which is higher than...

U.S. CoreValve High Risk trial TCT 2014

According to a new study, transcatheter aortic valve replacement (TAVR) provided meaningful clinical benefits relative to surgical aortic valve replacement (SAVR) in high risk patients with...